Loss-of-function mutations in the APOC3 gene are associated with reduced risk of coronary heart disease and ischaemic cardiovascular disease.
The lowdown: Two large-scale genetic validation studies have pointed the way to another putative cardiovascular target.
In a first study, members of the Exome Sequencing Project examined a cohort of 3,734 participants for mutations that were associated with low plasma triglyceride levels, a measure that has previously been associated with reduced cardiovascular risk. Carriers of a rare APOC3 mutation had plasma triglyceride levels that were 39% lower than those of non-carriers. When the researchers cross-validated the results by looking at the clinical importance of 4 loss-of-function APOC3 mutations in 110,970 participants from 14 studies, they found that the 498 participants that were heterozygous for loss-of-function mutations had a 40% lower risk of coronary heart disease than did non-carriers (N. Engl. J. Med. 371, 22–31; 2014).
In an independent study, Anders Berg Jørgensen from the University of Copenhagen, Denmark, and his colleagues found that loss-of-function APOC3 mutations were associated with a 44% reduction in non-fasting levels of triglycerides. Clinical follow-up of participants showed that the incidences of ischaemic vascular disease and ischaemic heart disease were reduced in carriers by 41% and 36%, respectively (N. Engl. J. Med. 371, 32–41; 2014).
“The results of our study highlight the potential usefulness of naturally occurring loss-of-function mutations in guiding the selection of therapeutic targets,” write the members of the Exome Sequencing Project. They compare their findings to the discovery of loss-of-function mutations in the gene coding for proprotein convertase subtilisin kexin 9 (PCSK9), which sparked the development of a highly anticipated class of antibody therapies for hypercholesterolaemia (Nature Rev. Drug Discov. 11, 817–819; 2012).
These data may be particularly important for Isis, which has an antisense APOC3 inhibitor in Phase II development for the treatment of elevated plasma triglycerides.
Rights and permissions
About this article
Cite this article
APOC3 joins genetically validated target list. Nat Rev Drug Discov 13, 566 (2014). https://doi.org/10.1038/nrd4408
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4408